p53 mutation and locoregional treatment failure in head and neck squamous cell carcinoma

Journal of the National Cancer Institute

Volumn 88, Issue 21, 1996, Pages 1580-1586

  Koch, Wayne M ^a   Brennan, Joseph A ^a   Zahurak, Marianna ^a   Goodman, Steven N ^a   Westra, William H ^a   Schwab, Donna ^a   Yoo, George H ^a   Lee, Ding Jen ^a   Forastiere, Arlene A ^a   Sidransky, David ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER GENETICS; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; FEMALE; GENE MUTATION; HEAD AND NECK CARCINOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; MOLECULAR GENETICS; SQUAMOUS CELL CARCINOMA; STATISTICAL ANALYSIS;

CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; DNA, NEOPLASM; GENES, P53; HEAD AND NECK NEOPLASMS; HUMANS; MUTATION; POLYMERASE CHAIN REACTION; SURVIVAL ANALYSIS; TREATMENT FAILURE;

EID: 10344250962     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/88.21.1580     Document Type: Article

References (37)

1. Harris CC, Hollstein M. Clinical implications of the p53 tumor-suppressor gene [see comment citations in Medline]. N Engl J Med 1993;329:1318-27.
2. Boyle JO, Hakim J, Koch WM, van der Riet P, Hruban RH, Roa RA, et al. The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res 1993;53: 4477-80.
3. Brennan JA, Boyle JO, Koch WM, Goodman SN, Hruban RH, Eby YJ, et al. Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck. N Engl J Med 1995;332:712-7.
4. Caamano J, Zhang SY, Rosvold EA, Bauer B, Klein-Szanto AJ. p53 alterations in human squamous cell carcinomas and carcinoma cell lines. Am J Pathol 1993;142:1131-9.
5. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, et al. p53 status and the efficacy of cancer therapy in vivo. Science 1994;266:807-10.
6. Lee JM, Bernstein A. p53 mutations increase resistance to ionizing radiation. Proc Natl Acad Sci USA 1993;90:5742-6.
7. Wynford-Thomas D. p53 in tumour pathology: can we trust immunocytochemistry? [editorial] [see comment citation in Medline]. J Pathol 1992;166:329-30.
8. Hall PA, Lane DP. p53 in tumour pathology: can we trust immunohistochemistry? - Revisited! [editorial] [see comment citation in Medline]. J Pathol 1994;172:1-4.
9. Gapany M, Pavelic ZP, Gapany SR, Pavelic L, Li YG, Craven JM, et al. Relationship between immunohistochemically detectable p53 protein and prognostic factors in head and neck tumors. Cancer Detect Prev 1993;17:379-86.
10. Frank JL, Bur ME, Garb JL, Kay S, Ware JL, Sismanis A, et al. p53 tumor suppressor oncogene expression in squamous cell carcinoma of the hypopharynx. Cancer 1994;73:181-6.
11. Sauter ER, Ridge JA, Gordon J, Eisenberg BL. p53 overexpression correlates with increased survival in patients with squamous-carcinoma of the tongue base. Am J Surg 1992;164:651-3.
12. Dolcetti R, Doglioni C, Maestro R, Gasparotto D, Barzan L, Pastore A, et al. p53 over-expression is an early event in the development of human squamous-cell carcinoma of the larynx: genetic and prognostic implications. Int J Cancer 1992;52:178-82.
13. Field JK, Malliri A, Butt SA, Gosney JR, Phillips D, Spandidos DA, et al. p53 expression in end stage squamous cell carcinoma of the head and neck prior to chemotherapy treatment: expression correlates with a very poor clinical outcome. Int J Oncol 1993;3:431-5.
14. Dursun G, Sak SD, Akyol G, Dursun A, Erekul S, Demireller A, et al. Overexpression of p53 in laryngeal carcinoma: clinicopathological implications. Ear Nose Throat J 1995; 74:645-8.
15. Roland NJ, Rowley H, Caslin AW, Jones AS. p53 expression in laryngeal carcinoma [abstr]. Otolaryngol Head Neck Surg 1995;113:80.
16. Caminero MJ, Nunez F, Suarez C, Ablanedo P. Immunohistochemical detection of p53 protein in human oropharyngeal carcinoma: prognostic implications [abstr]. Otolaryngol Head Neck Surg 1995;113:80-1.
17. Deutsch MD, Righi PD, Pavelic ZP, Gluckman JL. Increased survival in patients with p53-positive cervical metastases from an unknown primary [abstr]. Otolaryngol Head Neck Surg 1995;113:81.
18. Sauter ER, Ridge JA, Litwin S, Langer CJ. Pretreatment p53 protein expression correlates with decreased survival in patients with end-stage head and neck cancer. Clin Cancer Res 1995;1:1407-12.
19. Gasparini G, Bevilacqua P, Bonoldi E, Testolin A, Galassi A, Verderio P, et al. Predictive and prognostic markers in a series of patients with head and neck squamous cell invasive carcinoma treated with concurrent chemoradiation therapy. Clin Cancer Res 1995;1:1375-83.
20. Koempel JA, Portugal LG, Rubin SJ, Farolen MJ, Primer JI, Sabnani J, et al. The role of p53 as a predictor of response to primary radiation therapy and survival in early laryngeal carcinoma [Abstract]. Otolaryngol Head Neck Surg 1995;113:67.
21. Bradford CR, Zhu S, Wolf GT, Poore J, Fisher SG, Beals T, et al. Overexpression of p53 predicts organ preservation using induction chemotherapy and radiation in patients with advanced laryngeal cancer. Department of Veterans Affairs Laryngeal Study Group. Otolaryngol Head Neck Surg 1995;113:408-12.
22. Duffy MJ. Cellular oncogenes and suppressor genes as prognostic markers in cancer. Clin Biochem 1993;26:439-47.
23. Fisher CJ, Gillett CE, Vojtesek B, Barnes DM, Millis RR. Problems with p53 immunohistochemical staining: the effect of fixation and variation in the methods of evaluation. Br J Cancer 1994;69:26-31.
24. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49-53.
25. Sjogren S, Inganas M, Norberg T, Lindgren A, Nordgren H, Holmberg L, et al. The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. J Natl Cancer Inst 1996;88: 173-82.
26. Beahrs OH, Henson DE, Hutter RV, Myers MH, editors. American Joint Committee on Cancer. Manual for staging of cancer, 3rd ed. Philadelphia: Lippincott, 1988:27-62.
27. Baker SJ, Preisinger AC, Jessup JM, Paraskeva C, Markowitz S, Willson JK, et al. p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res 1990;50:7717-22.
28. Sidransky D, Von Eschenbach A, Tsai YC, Jones P, Summerhayes I, Marshall F, et al. Identification of p53 gene mutations in bladder cancers and urine samples. Science 1991;252: 706-9.
29. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
30. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50: 163-70.
31. Cox DR. Regression models and life tables. J R Stat Soc [B] 1972;34:187-220.
32. SAS Institute Inc. SAS User's Guide. Statistics, Version 5th ed. Cary, NC: SAS Institute Inc, 1985.
33. Statistics and Epidemiology Research Corporation. EGRET Users' Manual. Seattle: 1988.
34. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991;51:6304-11.
35. Renan MJ. How many mutations are required for tumorigenesis? Implications from human cancer data. Mol Carcinog 1993;7:139-46.
36. Wahl AF, Donaldson KL, Fairchild C, Lee FY, Foster SA, Demers GW, et al. Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nat Med 1996;2:72-9.
37. Shanmugaratnam K. Histological typing of tumours of the upper respiratory tract and ear. 2nd ed. Berlin/Heidelberg: Springer-Verlag, 1991.